Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy

Artificial Organs

Volumn 26, Issue 2, 2002, Pages 98-102

  Sikole, Aleksandar ^a,b   Polenakovic, Momir ^a   Spiroska, Vera ^a   Polenakovic, Biljana ^a   Klinkmann, Horst ^b   Scigalla, Paul ^c  

^a Medical Faculty   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anemia; Chronic renal failure; Left ventricular hypertrophy; Recombinant erythropoietin; Renal dialysis

Indexed keywords

BLOOD PRESSURE; CARDIOLOGY; ECHOCARDIOGRAPHY; HEMODIALYZERS; HEMODYNAMICS; PATHOLOGY; PATIENT TREATMENT;

ANEMIA; CARDIAC OUTPUT; CHRONIC RENAL FAILURE; HAEMATOCRIT; LEFT VENTRICULAR HYPERTROPHIES; LEFT VENTRICULAR MASS; MAJOR FACTORS; OUTPUT STATE; RECOMBINANT ERYTHROPOIETIN; RENAL DIALYSIS;

DIALYSIS;

ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEMATOCRIT; HEMODIALYSIS; HUMAN; MALE; MEAN ARTERIAL PRESSURE; MORPHOLOGY; MULTICENTER STUDY; PRIORITY JOURNAL; UREMIA; VASCULAR RESISTANCE;

EID: 0036121350     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2002.06839.x     Document Type: Article

References (32)

1. Reninangiotensin system: Genes to bedside
2. Basic determinants of myocardial hypertrophy: A review of molecular mechanisms
3. Cardiocyte adaptation to chronically altered load
4. Heart size
5. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study
6. The clinical course of left ventricular hypertrophy in dialysis patients
7. Impact of left ventricular hypertrophy on survival in end-stage renal disease
8. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
9. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men
10. Asymmetric septal hypertrophy and left atrial dilatation in patients with end-stage renal disease on longterm hemodialysis
11. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy
12. Purification of human erythropoietin
13. Cloning and expression of the human erythropoietin gene
14. Isolation and characterization of genomic and cDNA clones of human erythropoietin
15. Vascular changes in hemodialysis patients in response to recombinant human erythropoierin
16. Longterm cardiorespiratory effects of amelioration of renal anaemia by erythropoietin
17. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin
18. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients
19. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: Proposal for a hematocrit most beneficial to hemodynamics
20. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialyzed uraemic patients
21. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients
22. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients
23. Effects of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation
24. Hemodynamics of uremic anemia
25. Recommendations regarding quantitation in M-mode echocardiographic measurements
26. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asinergy
27. Left ventricular hypertrophy: Relationship of anatomic, echocardiographic and electrocardiographic findings
28. Cardiac work demands and left ventricular function in end-stage renal disease
29. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin
30. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels
31. Hypertension as a possible complication of recombinant human erythropoietin therapy